Integration of autologous dendritic cell-based immunotherapy in the standard of care treatment for patients with newly diagnosed glioblastoma: results of the HGG-2006 phase I/II trial
/in Dendritic Cells, Glioblastoma, International Publications, IOZK Veröffentlichungen /von 2012-04-22 / Cancer Immunol. Immunother. 2012 Nov;61(11):2033-44Construction of recombinant Newcastle disease virus Italien strain for oncolytic virotherapy of tumors
/in International Publications, Newcastle Disease Virus /von 2012-04-18 / Hum. Gene Ther. 2012 Jul;23(7):700-10Hyperthermia induces cytoskeletal alterations and mitotic catastrophe in p53-deficient H1299 lung cancer cells
/in Hyperthermia, International Publications /von 2012-04-06 / Acta Histochem. 2013 Jan;115(1):8-15Pre-clinical assessment of autologous DC-based therapy in ovarian cancer patients with progressive disease
/in Dendritic Cells, International Publications, Ovarian Cancer /von 2012-04-05 / Cancer Immunol. Immunother. 2012 Nov;61(11):1929-39Monitoring of regulatory T cell frequencies and expression of CTLA-4 on T cells, before and after DC vaccination, can predict survival in GBM patients
/in Dendritic Cells, Glioblastoma, International Publications /von 2012-04-02 / PLoS ONE 2012;7(4):e32614
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Das IOZK
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- Recent developments in targeting breast cancer stem cells (BCSCs): a descriptive review of therapeutic strategies and emerging therapies
- Neoantigen-targeted dendritic cell vaccination in lung cancer patients induces long-lived T cells exhibiting the full differentiation spectrum
- Individualized Multimodal Immunotherapy (IMI): Scientific Rationale and Clinical Experience from a Single Institution